Cassava Sciences Inc (SAVA)
22.02
+0.29
(+1.33%)
USD |
NASDAQ |
Apr 26, 13:48
Cassava Sciences Enterprise Value: 818.15M for April 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 25, 2024 | 818.15M |
| April 24, 2024 | 775.35M |
| April 23, 2024 | 767.14M |
| April 22, 2024 | 764.98M |
| April 19, 2024 | 727.81M |
| April 18, 2024 | 794.81M |
| April 17, 2024 | 798.26M |
| April 16, 2024 | 787.89M |
| April 15, 2024 | 743.80M |
| April 12, 2024 | 862.24M |
| April 11, 2024 | 1.007B |
| April 10, 2024 | 938.31M |
| April 09, 2024 | 976.78M |
| April 08, 2024 | 897.68M |
| April 05, 2024 | 799.99M |
| April 04, 2024 | 764.12M |
| April 03, 2024 | 768.44M |
| April 02, 2024 | 730.83M |
| April 01, 2024 | 755.90M |
| March 28, 2024 | 755.90M |
| March 27, 2024 | 761.52M |
| March 26, 2024 | 730.83M |
| March 25, 2024 | 730.40M |
| March 22, 2024 | 735.16M |
| March 21, 2024 | 794.37M |
| Date | Value |
|---|---|
| March 20, 2024 | 828.52M |
| March 19, 2024 | 829.39M |
| March 18, 2024 | 798.70M |
| March 15, 2024 | 799.13M |
| March 14, 2024 | 773.19M |
| March 13, 2024 | 771.46M |
| March 12, 2024 | 778.38M |
| March 11, 2024 | 675.94M |
| March 08, 2024 | 690.63M |
| March 07, 2024 | 710.95M |
| March 06, 2024 | 736.45M |
| March 05, 2024 | 804.32M |
| March 04, 2024 | 851.86M |
| March 01, 2024 | 873.04M |
| February 29, 2024 | 872.18M |
| February 28, 2024 | 870.02M |
| February 27, 2024 | 873.04M |
| February 26, 2024 | 826.36M |
| February 23, 2024 | 805.12M |
| February 22, 2024 | 829.62M |
| February 21, 2024 | 814.41M |
| February 20, 2024 | 827.93M |
| February 16, 2024 | 881.99M |
| February 15, 2024 | 916.62M |
| February 14, 2024 | 896.77M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-1.561M
Minimum
May 20 2019
5.135B
Maximum
Jul 28 2021
871.99M
Average
777.36M
Median
Apr 10 2023
Enterprise Value Benchmarks
| Amylyx Pharmaceuticals Inc | -250.71M |
| MannKind Corp | 1.104B |
| Clearside Biomedical Inc | 65.23M |
| Lantern Pharma Inc | 17.34M |
| NovaBay Pharmaceuticals Inc | 2.275M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -20.92M |
| Total Expenses (Quarterly) | 22.79M |
| EPS Diluted (Quarterly) | -0.50 |
| Earnings Yield | -10.54% |
| Operating Earnings Yield | 3.40% |
| Normalized Earnings Yield | 21.62 |